Key Highlights
- STAAR Surgical closed up 7.49% at $20.51 after authorizing a $50 million share repurchase.
- The stock traded near the top of its session range, though on trading Volume below the typical full-session level.
- Trailing-twelve-month Revenue was $339.59 million, up 51.3% year over year, though net Margin remained thin at 1.1%.
STAAR Surgical (NASDAQ:STAA) authorized a $50 million share repurchase, with shares closing up 7.49% at $20.51. The announcement represents a corporate capital-allocation decision, while the share-price increase reflects how the market valued the news. A repurchase authorization gives the company permission to use the designated amount to buy its own shares, though it does not establish how quickly purchases will occur.
The $50 Million Repurchase Authorization
The authorization establishes the amount the company may allocate toward buying back its own shares, rather than confirming that all of the money has already been spent. STAA shares remain down over the past year and month, so the authorization arrives while the stock is below its earlier levels over both measured periods. Investors can compare the size of the authorization with the reported market Capitalization of about $1 billion.
Support Meets Resistance
STAA trades below its 20-day Moving Average of $22.13, its 50-day average of $23.29, and its 200-day average of $23.73. The 14-day RSI is 40.0. The MACD at -1.07 sits below its -0.84 signal line. The nearest downside reference is first support at $19.06, while first resistance is $20.82, followed by second resistance at $25.30.
Revenue Growth Meets Thin Profitability
Trailing-twelve-month revenue was $339.59 million, representing 51.3% year-over-year growth, while gross margin reached 74.8%. Operating Margin was 18.0%, materially below the gross margin after operating expenses are included. Net margin was 1.1%, showing only a thin portion of reported revenue remained at the bottom line. The Debt-to-Equity Ratio was 0.10, with $148.58 million of cash and equivalents and 957 employees.
Peers Moving on This News
- Bioventus (NASDAQ:BVS) little changed
- OrthoPediatrics (NASDAQ:KIDS) down 0.7%
- Cerus (NASDAQ:CERS) down 0.4%



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...